- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04595682
Estradiol Effects on Alcohol Across the Menstrual Cycle
Estradiol Effects on Behavioral and Reward Sensitivity to Alcohol Across the Menstrual Cycle
This study will provide the first rigorous integrative test of the hypothesis that rapid rises in estradiol (a female hormone) increase the rewarding and disinhibiting effects of alcohol and that such increased sensitivity correlates with increased alcohol use. Identification of the behavioral mechanisms by which estradiol surges can increase alcohol use would provide a critical advancement of neurobiological theory of alcohol abuse in women, an understudied area, as well as provide new directions for personalization of alcohol abuse treatment in women.
In this study, naturally-cycling women will be examined daily over their menstrual cycle using an integrative combination of daily ecological assessments of hormone fluctuations and alcohol use along with strategically-timed laboratory tests of their acute sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40504
- University Of Kentucky Psychology Research Lab
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- female
- regular menstrual cycle
- consume alcohol at least once per week
- no history of drug or alcohol dependence
Exclusion Criteria:
- use of hormone-based medications
- irregular menstrual cycle
- current pregnancy
- primary sensorimotor handicap
- frank neurological disorder
- pervasive developmental disorder
- frank psychosis
- diagnosed intellectual disability
- medical condition contraindicating alcohol use
- substance abuse history (except nicotine)
- body mass index (BMI) 30 or above
- alcohol abstainer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: menstrual cycle
Participants will have their alcohol sensitivity test once during their early follicular phase and once during their late follicular phase
|
Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase.
The test battery consists of measures of rewarding effects and alcohol (or placebo) effects on disinhibition and impulsive choice.
The placebo consists of 300 ml of lemon-flavored soda with a small amount (3 ml) of alcohol floated on top.
Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase.
The test battery consists of measures of rewarding effects and alcohol effects on disinhibition and impulsive choice.
The alcohol dose consists of 0.60 g/kg absolute alcohol that produces a peak blood-alcohol concentration of 80 mg/dl.
Doses will be mixed with a carbonated, non-caffeinated, lemon-flavored soda and consumed within 10 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Attentional Bias (Early Follicular Phase)
Time Frame: 1 day
|
Attentional bias is measured by the visual dot-probe task and provides an implicit assessment of the rewarding properties of alcohol as indicated by the degree to which an acute dose of alcohol increases the drinker's attention to alcohol cues is measured.
Subjects look at images on a screen and their attention to various images is measured.
An alcohol-related image and a neutral control image are presented briefly side-by-side, on a computer screen.
An eye tracker embedded into the monitor provides an unobtrusive measure of the duration (dwell time) that volunteers look at each image.
|
1 day
|
|
Attentional Bias (Late Follicular Phase)
Time Frame: 1 day
|
Attentional bias is measured by the visual dot-probe task and provides an implicit assessment of the rewarding properties of alcohol as indicated by the degree to which an acute dose of alcohol increases the drinker's attention to alcohol cues is measured.
Subjects look at images on a screen and their attention to various images is measured.
An alcohol-related image and a neutral control image are presented briefly side-by-side, on a computer screen.
An eye tracker embedded into the monitor provides an unobtrusive measure of the duration (dwell time) that volunteers look at each image.
|
1 day
|
|
Disinhibition (Early Follicular Phase)
Time Frame: 1 day
|
Disinhibition wil be measured by the cued go/no-go task, which requires participants to respond quickly to go targets and inhibit responses to no-go targets. Participants complete 250 trials in which they are presented with a cue, followed by a target. A go target is green, and participants are instructed to press a button when presented with a go target. A no-go target is blue, and participants are instructed to do nothing when this appears. A go cue predicts a go target with 80% accuracy, whereas a no-go cue predicts a no-go target with 80% accuracy. The condition of interest is when a go cue is followed by a no-go target. The proportion reported is the proportion of trials under this condition in which participants press the button (expecting a go target but presented with a no-go target). |
1 day
|
|
Disinhibition (Late Follicular Phase)
Time Frame: 1 day
|
Disinhibition wil be measured by the cued go/no-go task, which requires participants to respond quickly to go targets and inhibit responses to no-go targets. Participants complete 250 trials in which they are presented with a cue, followed by a target. A go target is green, and participants are instructed to press a button when presented with a go target. A no-go target is blue, and participants are instructed to do nothing when this appears. A go cue predicts a go target with 80% accuracy, whereas a no-go cue predicts a no-go target with 80% accuracy. The condition of interest is when a go cue is followed by a no-go target. The proportion reported is the proportion of trials under this condition in which participants press the button (expecting a go target but presented with a no-go target). |
1 day
|
|
Subjective Ratings of the Rewarding Effects of Alcohol (Early Follicular Phase)
Time Frame: 1 day
|
a visual analog scale from 0-100, with 0 being not rewarding at all and 100 being very rewarding
|
1 day
|
|
Subjective Ratings of the Rewarding Effects of Alcohol (Late Follicular Phase)
Time Frame: 1 day
|
a visual analog scale from 0-100, with 0 being not rewarding at all and 100 being very rewarding
|
1 day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michelle Martel, PhD, University Of Kentucky
- Principal Investigator: Mark Fillmore, PhD, University Of Kentucky
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 52637
- 1R01AA027990-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Use, Unspecified
-
University of Rhode IslandCompletedAlcohol Use, UnspecifiedUnited States
-
Women's College HospitalRecruitingAlcohol; Harmful Use | Tobacco Use | Tobacco Use Cessation | Alcohol Use, UnspecifiedCanada
-
Zeno Functional Foods, LLCINQUIS Clinical Research Ltd.CompletedAlcohol Use, UnspecifiedCanada
-
University of WashingtonNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Enrolling by invitationAlcohol Use, UnspecifiedUnited States
-
University of MichiganNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol Use, UnspecifiedUnited States
-
Pivot Health Technologies Inc.Withdrawn
-
Virginia Commonwealth UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Completed
-
University of Central FloridaCompleted
-
H. Lee Moffitt Cancer Center and Research InstituteNational Institutes of Health (NIH); National Center for Complementary and...CompletedTobacco Use | Alcohol Use, UnspecifiedUnited States
-
UConn HealthNational Institute on Alcohol Abuse and Alcoholism (NIAAA); University of TexasRecruitingAlcohol Use, UnspecifiedUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States